Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders

GBT Accepting Proposals for 2020 ACCEL Grants to Support Novel Access-to-Care Programs for People Living with Sickle Cell Disease

Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress

Foundation Medicine and Chugai Announce Partnership with National Cancer Center for the Use of FoundationOne®Liquid in the Third Stage of SCRUM-Japan